Insmed's Brensocatib Becomes First FDA-Approved Treatment for Non-Cystic Fibrosis Bronchiectasis
TL;DR
Insmed received FDA approval for its lung disease drug brensocatib, marketed as Brinsupri for bronchiectasis, with potential peak sales of $5 billion, positioning it as a major growth driver for the company, which is also seeking approvals in Europe, the U.K., and Japan.
- Insmed’s lung disease drug approved in the U.S. statnews.com
- FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease Insmed Incorporated Investor Relations
- Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor Fierce Pharma
- Insmed gets FDA approval for the first DPP1 inhibitor, in lung disease Endpoints News
- US FDA approves Insmed's drug as first treatment for a chronic lung disease Reuters
Want the full story? Read the original reporting
Read on statnews.com